Regency Centers Corp (REG) Stock News

A securities class action lawsuit has been filed against FuelCell Energy, Inc. (FCEL) for allegedly making false and misleading statements regarding manufacturing capacity, production rates, and profitability. The lawsuit covers purchases between June 24, 2026 and September 1, 2026, with a lead plaintiff deadline of November 10, 2026. Investors who purchased FCEL securities during this period may be eligible for compensation.

A securities class action lawsuit has been filed against XTI Aerospace, Inc. for allegedly making materially false and misleading statements during April 15 - August 17, 2026. The lawsuit claims senior executives engaged in undisclosed activities that affected disclosure controls and prevented timely earnings report filings. Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is October 27, 2026.

Rosen Law Firm is soliciting investors who purchased Papa John's International (PZZA) stock between August 7, 2025 and August 5, 2026 to join a securities class action lawsuit. The lawsuit alleges that Papa John's made materially false and misleading statements about its transformation efforts, which were taking longer than expected and failed to prevent market share losses, ultimately requiring a shift toward increased promotional efforts.

Rosen Law Firm is notifying investors about securities class action lawsuits, including one against Hyliion Holdings Corp. for allegedly making false statements about its VFG Holdings partnership and commercial pipeline credibility. The firm is seeking a lead plaintiff by October 27, 2026, and encourages affected investors to join the litigation.

A securities class action lawsuit has been filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging that the company made materially false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA reportedly raised serious safety concerns, including device malfunctions causing dangerously high insulin dosing and hypoglycemic events, with thousands of complaints filed. The company allegedly failed to implement meaningful corrective actions. Investors who purchased BBNX stock between July 30, 2025 and February 24, 2026 may be eligible for compensation, with a November 3, 2026 deadline to serve as lead plaintiff.

Rosen Law Firm announces a September 22, 2026 deadline for investors to join a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges the company made materially false statements regarding its handpiece unit sales and revenues, claiming an undisclosed discount program artificially inflated sales figures, created excess inventory of over 10,000 units, and that the company could not achieve its 2025 guidance.

A securities class action lawsuit has been filed against Rackspace Technology, Inc. for allegedly making false and misleading statements regarding its business operations. The lawsuit claims defendants failed to disclose that enterprise AI efforts would require significant reallocation of resources from the profitable Private Cloud segment, that Public Cloud revenue was declining, and that fiscal year 2026 revenue would be significantly impacted. Investors who purchased securities between May 7, 2026 and July 8, 2026 may be eligible for compensation. The lead plaintiff deadline is September 28, 2026.

Rosen Law Firm has filed securities class action lawsuits against Blaize Holdings, Hyliion Holdings, and Primoris Services Corporation, alleging false statements and improper revenue recognition. Investors who purchased securities during specified class periods are encouraged to join the litigation before upcoming deadlines, with the lead plaintiff deadline for Blaize set for October 5, 2026.

Rosen Law Firm reminds investors in Cogent Communications Holdings, Inc. (NASDAQ: CCOI) who purchased stock between February 29, 2024 and May 1, 2026 of the September 21, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding optical wavelength backlog, customer demand, revenue targets, dividend sustainability, and undisclosed risks related to insider stock pledging activities.

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals over allegations that the company made false and misleading statements regarding a Phase 3 clinical trial of Fianlimab for melanoma treatment. The trial failed to reach statistical significance on its primary endpoint, causing an $11 billion market cap loss. Investors claim Regeneron concealed flawed statistical assumptions and slow event rates while expressing confidence in the trial's success. The lead plaintiff deadline is September 14, 2026.

Rosen Law Firm is notifying investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) of a securities class action lawsuit with a September 22, 2026 lead plaintiff deadline. The lawsuit alleges that PROCEPT made materially false statements regarding its sales practices, including use of undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess inventory of over 10,000 units, and made unachievable 2025 guidance. Investors with losses exceeding $100,000 are encouraged to seek counsel.

Pomerantz Law Firm has filed class action lawsuits against Regeneron Pharmaceuticals, Capricor Therapeutics, and GPGI, Inc. for alleged securities fraud. The primary focus is on Regeneron, where a Phase III clinical trial for Fianlimab-Libtayo failed to meet its primary endpoint, causing the stock to decline significantly on two separate occasions in April and May 2026. Investors with losses are urged to contact the firm by September 14, 2026, to potentially become lead plaintiffs.

Phillips Edison & Company (PECO) presents a better value opportunity than Regency Centers (REG) based on Zacks Rank and Style Scores analysis. PECO holds a #2 Buy rating with a Value grade of B, while REG has a #3 Hold rating with a Value grade of D. PECO's forward P/E of 14.07 and PEG ratio of 2.02 are more favorable than REG's forward P/E of 15.49 and PEG ratio of 4.47.

Rosen Law Firm has filed a class action lawsuit against Innventure, Inc. (NASDAQ: INV) on behalf of investors who purchased securities between November 17, 2025 and August 13, 2026. The lawsuit alleges that defendants made materially false and misleading statements regarding Accelsius Holdings LLC's transformative deal with DarkNX, which allegedly was unlikely to materialize, and that revenue and cash flow targets for 2026 were overstated. Investors must move the court by October 27, 2026 to serve as lead plaintiff.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against Alibaba Group Holding Limited. The lawsuit alleges that Alibaba made false and misleading statements regarding its control by the Chinese Ministry of Industry and Information Technology (MIIT), which would classify it as a Chinese military company under the National Defense Authorization Act, and failed to disclose ongoing distillation attacks against third-party AI models. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is notifying investors of securities class action lawsuits against Blaize Holdings, GoDaddy Inc., and Rackspace Technology. The lawsuits allege false statements, improper revenue recognition, and misleading disclosures. Investors have until specified deadlines to join as lead plaintiffs or class members.

A securities class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly making false and misleading statements about its Phase 3 clinical trial of Fianlimab for melanoma treatment. The company reportedly failed to disclose that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. After initially expressing confidence in the trial, Regeneron altered the trial protocol in November 2025 without timely disclosure and ultimately announced on May 15, 2026 that the trial failed to reach statistical significance, resulting in an $11 billion market cap loss.

Rosen Law Firm is reminding investors who purchased Datavault AI Inc. securities between September 4, 2024 and October 30, 2025 of an important October 5, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that defendants made materially false statements regarding corporate partnerships, overstated trading activity on the Datavault Platform, and failed to disclose connections with a convicted felon, causing reputational harm.

A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) alleging that defendants made false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. Investors who purchased securities between March 9, 2026 and June 24, 2026 may be entitled to compensation. The lead plaintiff deadline is October 5, 2026.

Rosen Law Firm is notifying investors who purchased Hertz Global Holdings (NASDAQ: HTZ) common stock between May 7, 2026 and June 23, 2026 of an important September 22, 2026 deadline to serve as lead plaintiff in a securities class action lawsuit. The lawsuit alleges that Hertz made materially false and misleading statements regarding its liquidity position, mischaracterizing market softness as transitory when it was actually recurring, and failing to disclose the need for a dilutive, distressed capital raise that would harm shareholders.

Rosen Law Firm reminds investors of the September 22, 2026 lead plaintiff deadline in a securities class action against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its discount programs, handpiece unit sales, and revenue guidance. The company allegedly used undisclosed bulk order discounts that artificially inflated sales figures and created excess inventory of over 10,000 units, exposing the company to material operational and financial risks.

REGL is a smart beta ETF focused on mid-cap dividend aristocrats with $1.78 billion in assets. The fund has delivered 12.47% returns year-to-date and 10.97% over the past year, with a 2.17% dividend yield and 0.40% expense ratio. It carries medium risk with a beta of 0.71 and holds about 66 stocks across financials, industrials, and utilities sectors.

A securities class action lawsuit has been filed against Pentwater Capital Management LP and its CEO Matthew Halbower, alleging they orchestrated a market manipulation scheme involving Avis Budget Group stock. The defendants, holding approximately 51% economic interest in Avis, allegedly engaged in aggressive stock purchases during February 2025 to April 2026 that triggered a short squeeze, artificially inflating the stock price and benefiting their holdings. Investors who purchased Avis securities during this period may be eligible for compensation, with a September 29, 2026 deadline to serve as lead plaintiff.

Klépierre, Europe's leading shopping mall operator, has raised its full-year 2026 guidance with EBITDA expected to reach a minimum of €1,150 million. The company demonstrated strong execution in a dynamic retail market, driving organic growth. As of July 31, 2026, the company had 286.86 million shares outstanding.

The Schall Law Firm is seeking investors to join a class action lawsuit against Regeneron Pharmaceuticals for securities fraud. The company allegedly made false and misleading statements about its Phase III Fianlimab-Libtayo study, claiming it was likely to succeed when it actually failed to demonstrate clinical differentiation from competing therapies. Investors who purchased securities between August 1, 2025 and May 15, 2026 are encouraged to participate before the September 14, 2026 deadline.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made false statements about trial progress while concealing that preliminary statistical assumptions were flawed and the treatment showed no meaningful differentiation over standard therapies. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026.

Rosen Law Firm is notifying investors about multiple securities class action lawsuits. The primary focus is on Erasca, Inc., which allegedly made false and misleading statements about its lead oncology drug candidate ERAS-0015, claiming it was 'best-in-class' while failing to disclose improper comparisons to competitors and lacking reasonable basis. The firm is seeking lead plaintiffs with an August 10, 2026 deadline for Erasca and August 4, 2026 for PicS N.V.

A securities fraud class action lawsuit has been filed against Regeneron Pharmaceuticals for allegedly misleading investors about the success of its Phase III Fianlimab-Libtayo clinical trial. The stock dropped 6.2% on April 29, 2026, and 9.8% on May 15, 2026, after the company announced the study failed to achieve statistical significance. Investors have until September 14, 2026, to request lead plaintiff status.

Regeneron Pharmaceuticals faces a securities class action lawsuit after failing to disclose critical information about its Phase 3 clinical trial for a melanoma treatment combination therapy. The company allegedly made misleading statements about the trial's progress while concealing that preliminary statistical assumptions were flawed and the primary endpoint was unlikely to be achieved. The trial ultimately failed to reach statistical significance, resulting in an $11 billion market cap loss. The class period covers August 1, 2025 to May 15, 2026, with a lead plaintiff deadline of September 14, 2026.

Rosen Law Firm reminds GeneDx Holdings Corp. (NASDAQ: WGS) investors who purchased stock between April 16, 2025 and May 4, 2026 of the August 3, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges GeneDx made false statements regarding the Fabric acquisition's positive impact on the company's financials and operations, when defendants knew of significant viability problems that would negatively impact the business.